explore -WSS

explore

author：comprehensive 2025-09-30 17:03:52 - browse：4687

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Does Paxlovid work in people vaccinated against Covid

focus

WSS

Risky weight loss products often used by teens globally, per study

Merck to acquire Harpoon Therapeutics for $680 million

The SUPPORT Act is critical to fighting the opioid crisis

American taxpayers paid $1.8 trillion in health care costs in 2022

Ascension's ugly legal battle over care for poor patients in Texas

Readout LOUD podcast: live from JPM 2024

knowledge

explore

knowledge

At least 13 dead in Texas as scorching temps continue

Biotech reporter’s notebook: A sunnier mood at JPM 2024

The high cost of giving birth even with insurance

Nonprofit, backed by Microsoft, to certify AI tools in health care

Malaria cases in Florida and Texas: Here’s what you need to know

Nonprofit, backed by Microsoft, to certify AI tools in health care

Sports medicine is finally prioritizing gender equality

GSK to buy asthma

Virginia high school admissions case could be legal follow

Study suggests new cause of Down syndrome: cells linked to aging

hotspot

Heart disease and mental health: A look at cardiac psychology

Caregivers of transplant patients call for more support, training

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Fauci’s Covid grilling leads GOP to weigh foreign research rules

JPM pitch from hospitals? Revenue streams outside of patient care

focus

hotspot

focus

focus